Navigation Links
Misplaced Priorities in Medicaid Dispensation

Olympia: Its Audit time and things are coming under the microscope. Coughing up for health care for the needy, cost the exchequer a whopping sum and while they struggled // to make the amount, taxpayers at Washington were paying up for frivolous operations like a sex change, penile implants and breast lift up jobs, to suit people’s fancy.

Auditor Brian Sonntag, found many fishy areas in the Medicaid expenses with thousands of dubious expenditures in 2004 fiscal year. One account in particular threw him off balance – Where Medicaid had forked out a whopping $9,549.92 for a sex change surgery. It is extremely disconcerting when the needy, like the old people, do not get medications while on the other hand, and tax money is spent on frill surgeries, which is certainly not a do or die situation.

Officials at the Department of Social and Health Services have disagreed with many of the report accusations. Sontag, however holds the stance that there is enough evidence in the report to suggest that tens of millions of dollars have been spent on questionable procedures.

Drug Potter, The State Medicaid Director, is extremely upset with Sonntag’s conclusion and said “The debate would be whether or not they were medically necessary, and medical necessity is a term that is, as we speak, is undergoing revision. ... There are many things that we have traditionally paid for that were deemed medically necessary that we are calling into question on a more frequent basis."

According to Drug Potter, a sex-change operation, diagnosed as Gender dysphoria, is a psychological condition suffered by the patient, and the surgery is an obvious corrective measure. Therefore it can rightfully come under the purview of Medicaid.

Now, Medicaid stipulates patients to experiment with less costly treatment methods the before taking the final step of a sex change operation. According to Potter, the scrutiny does not indicate non-reimbursement for suc
'"/>




Page: 1 2

Related medicine news :

1. Misplaced Bravado: A Career In Surgery Eludes Women?
2. Concerns About Working Overtime May Be Misplaced
3. Women And Africa Top Priorities For WHO
4. Medicaid cuts leave patients in a lurch
5. Homecare Association Highlights Cost-Effectiveness of Medicare and Medicaid
6. Bush Administration to Exempt Medicaid Recipients on Proof of Citizenship
7. Few Medicaid Kids with Asthma Get Recommended Flu Shot
8. Medicaid Security Riddled with Flaws
9. Lowest Spending growth in US Medicaid
10. New Medicaid Rule For New Borns
Post Your Comments:
(Date:5/16/2008)...rstCall/ -- Tempo Participacoes,S.A. (Bovespa: TEM...ding,provider of healthcare administration service... services, announces today its results for the fir...formation contained herein,except where otherwise...,accordance with Brazilian Stock Exchange Commissi...
(Date:5/15/2008)...sing in Targeting Cancer Cells, ...ay 15 /PRNewswire-FirstCall/ -- Abbott scientists,...everal investigative,compounds in the company,s on... Clinical Oncology (ASCO) Annual Meeting, schedule... ABT-263, a Bcl-2 family protein,antagonist, and A...
(Date:5/15/2008)...ng cancer treatment for each individual, researche...resented a study suggesting a simple blood test ca...cacy for patients with metastatic breast cancer. ,...to determine if a particular cancer treatment is w...y significant radiographic changes in tumor size o...
(Date:5/15/2008)...tCall/ -- Digital Power,Corporation (Amex: DPW ) ...cial results for the first quarter ended March 31,...000 for the quarter ended,March 31, 2008, an incre...last year. An operating loss of $165,000 for the f...operating profit of $25,000 for the same quarter,l...
Breaking Medicine News(10 mins):Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 2Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 3Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 4Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 5Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 6Health News:Study suggests blood test can help improve treatment outcomes for breast cancer patients 2Health News:Digital Power Reports Financial Results for the First Quarter Ended March 31, 2008 2Health News:Digital Power Reports Financial Results for the First Quarter Ended March 31, 2008 3
... North America with an estimated 400,000 people fa...of these //people have their hearts pumping again ...of the main causes of death after the heart is res...esented at the 2006 Society for Academic Emergency...
...cos here have collapsed due to fasting in the past...fight against// reservation for backward classes w...ecision. "Ninety-four doctors have so far collapse...e hunger strike. Currently 35 of them are still si...
...people to get themselves screened for HIV, city-ru...criteria// for HIV testing. According to the new r...ent is not neccessary for voluntary HIV/AIDS testi...consent from the patient. This rule makes it the ...
...e discovered the cause for people to overeat. Scie...it's in the brain//. Researchers at the council's... the first neurobiological proof as to why some pe...research, published today in the Journal of Neuros...
Other Medicine News:Health News:Survival After Cardiac Arrest Is Aided By Cooling 2Health News:Despite Collapse Of The Medicos Strike To Continue Unabated 2Health News:Research Scans Explain Why People Crave For Food 2
(Date:5/16/2008)...r Novel Approach to Blood ...wire-FirstCall/ -- Pharmacopeia (Nasdaq:,PCOP), an...el small,molecule therapeutics, announced today th...or Antagonist (DARA), showed statistically signifi... in patients with mild to,moderate hypertension. P...
(Date:5/15/2008)...- Eisai Corporation of North,America announced tod...out,compounds in the company,s oncology pipeline, ...h have been accepted for presentation at the,44th ... Oncology (ASCO),taking place in Chicago from May... on Eisai marketed products and,investigational co...
(Date:5/15/2008)...ety profile of BSI-201 in subjects...May 15 /- BiPar Sciences, Inc., a,pri...ovel cancer therapies,today announced that data s...e presented at the 2008 American Society of Clinic...will be presented from the first in human Phase 1 ...
(Date:5/15/2008)...rstCall/ -- Cytopia Limited,(ASX: CYT) today annou...ntation on CYT997 at the 2008 Annual Meeting of th...l be accessible to the public via ASCO,s,website ... (US EDT)., The oral presentation, entitled "Phas...scular disrupting agent, in patients with advanced...
Breaking Medicine Technology:Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Tata Consultancy Services to Support Roches Global Capacity Building Initiative 455 1Tata Consultancy Services to Support Roches Global Capacity Building Initiative 455 2Tata Consultancy Services to Support Roches Global Capacity Building Initiative 455 3Mega Events in September Allow Heart Health Campaign to Reach Tens of Thousands of Hispanics During Cholesterol Awareness Month 450 1Mega Events in September Allow Heart Health Campaign to Reach Tens of Thousands of Hispanics During Cholesterol Awareness Month 450 2Mega Events in September Allow Heart Health Campaign to Reach Tens of Thousands of Hispanics During Cholesterol Awareness Month 450 3Mega Events in September Allow Heart Health Campaign to Reach Tens of Thousands of Hispanics During Cholesterol Awareness Month 450 4Mega Events in September Allow Heart Health Campaign to Reach Tens of Thousands of Hispanics During Cholesterol Awareness Month 450 5Mega Events in September Allow Heart Health Campaign to Reach Tens of Thousands of Hispanics During Cholesterol Awareness Month 450 6Nanotechnology 3A Whats that 3F 244 1Nanotechnology 3A Whats that 3F 244 2Avocados may help prevent oral cancer OSU study shows 443 1Avocados may help prevent oral cancer OSU study shows 443 2
...LIS, France, May 11, 2007 /PRNewswire-FirstCall/ -...ate on the phase 2a,study for NCX 1000, which is c...harma Inc. A preliminary analysis of 11 patients,...nsion confirmed,the safety profile of NCX 1000 but...ort the continuation of this clinical trial. As a,...
...(BUSINESS WIRE)--May 14, 2007 - Acceleron Pharma,...peutics for the,treatment of musculoskeletal, meta... results of a preclinical study with,ACE-031 that ...se,muscle mass and strength in normal mice and in ...its negative regulators of muscle,to increase musc...
Other Medicine Technology:NicOx Provides an Update on the Phase 2a Study for NCX 1000,Conducted With Axcan 2NicOx Provides an Update on the Phase 2a Study for NCX 1000,Conducted With Axcan 3Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in,Preclinical Studies 2Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in,Preclinical Studies 3
...: The HF-compatible V series from Pentax, the stan...asured., ,The HF-compatible series of fibre bronc...V and FB-15V models along with the very slim FB-10... quality thanks mainly to the higher resolution an...
...m the latest 60 series bronchoscopes., ,Olymp... providing clinicians with superior specifications...ressive range of fiberoptic instruments for diagno...he demands of increasing peripheral bronchoscopy.,...
The BRO-YP2 is Fujinon's pediatric fiberoptic bronchoscope. Its small outside diameter allows for more comfortable transnasal insertion. The standard 2.0mm channel provides sufficient suction and acc
...m the latest 60 series bronchoscopes., ,Olymp... providing clinicians with superior specifications...ressive range of fiberoptic instruments for diagno...he demands of increasing peripheral bronchoscopy.,...
Medicine Products: